BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaplan JE, Masur H, Holmes KK, Freedberg KA, Holtgrave D, Piscitelli SC, Van Dyke R, Watts H. An overview of the 1999 US Public Health Service/Infectious Diseases Society of America guidelines for preventing opportunistic infections in human immunodeficiency virus-infected persons. Clin Infect Dis 2000;30 Suppl 1:S15-28. [PMID: 10770912 DOI: 10.1086/313844] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Atkinson A, Zwahlen M, Barger D, d'Arminio Monforte A, De Wit S, Ghosn J, Girardi E, Svedhem V, Morlat P, Mussini C, Noguera-Julian A, Stephan C, Touloumi G, Kirk O, Mocroft A, Reiss P, Miro JM, Carpenter JR, Furrer H; Opportunistic Infections Project Working Group of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. Clin Infect Dis 2021;73:195-202. [PMID: 32448894 DOI: 10.1093/cid/ciaa615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9:493-504. [PMID: 19628174 DOI: 10.1016/s1473-3099(09)70175-6] [Cited by in Crossref: 373] [Cited by in F6Publishing: 397] [Article Influence: 26.6] [Reference Citation Analysis]
3 Hanson KE, Alexander BD, Perfect J. Drug Resistance in Cryptococcus neoformans. Antimicrobial Drug Resistance 2009. [DOI: 10.1007/978-1-60327-595-8_20] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
4 Andersson K, Chung RT. Hepatitis C Virus in the HIV-infected patient. Clin Liver Dis 2006;10:303-20, viii. [PMID: 16971263 DOI: 10.1016/j.cld.2006.05.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
5 Franklin JA, Flynn PM. Infectious disease complications in leukemia. Childhood Leukemias 2006. [DOI: 10.1017/cbo9780511471001.033] [Reference Citation Analysis]
6 Gayet-ageron A, Baratin D, Marceillac E, Allard R, Peyramond D, Chidiac C, Trepo C, Livrozet J, Touraine J, Ritter J, Sepetjan M, Fabry J, Vanhems P. The AIDS epidemic in Lyon: patient characteristics and defining illnesses between 1985 and 2000. HIV Med 2004;5:163-70. [DOI: 10.1111/j.1468-1293.2004.00205.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
7 Pruett BD, Baddour LM. Sinopulmonary complications of illicit drug use. Infect Dis Clin North Am 2002;16:623-43, viii. [PMID: 12371119 DOI: 10.1016/s0891-5520(02)00020-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
8 Afeltra J, Meis JF, Mouton JW, Verweij PE. Prevention of invasive aspergillosis in AIDS by sulfamethoxazole. AIDS 2001;15:1067-8. [PMID: 11399994 DOI: 10.1097/00002030-200105250-00020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]